NCT05124392 is a clinical trial in CJD (Creutzfeldt Jakob Disease), sponsored by Massachusetts General Hospital.

Who is sponsoring NCT05124392?

NCT05124392 is sponsored by Massachusetts General Hospital.

What condition does NCT05124392 study?

NCT05124392 studies CJD (Creutzfeldt Jakob Disease), Prion Diseases, GSS, FFI, Familial Fatal Insomnia.

Is NCT05124392 still recruiting?

NCT05124392 is currently recruiting now. Last updated 24 November 2025.

Last reviewed 2025-11-24 · How we verify

NCT05124392

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarker Profiling in Individuals at Risk for Prion Disease

Recruiting now Last updated 24 November 2025

What this trial tests

trial in CJD (Creutzfeldt Jakob Disease) in 150 participants. Currently enrolling.

Timeline

1 December 2017

Primary endpoint
1 June 2027

1 June 2027

Quick facts

Lead sponsor	Massachusetts General Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 December 2017
Primary completion	1 June 2027
Estimated completion	1 June 2027
Sites	1 location across United States

Conditions studied

CJD (Creutzfeldt Jakob Disease) — all drugs for CJD (Creutzfeldt Jakob Disease) →
Prion Diseases — all drugs for Prion Diseases →
GSS — all drugs for GSS →
FFI — all drugs for FFI →

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 85, any sex, with CJD (Creutzfeldt Jakob Disease) or Prion Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the direction of future clinical trials.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fluid Biomarkers in Individuals at Risk for Genetic Prion Disease up to Disease Conversion.
Vallabh SM, Mortberg MA, Allen SW, Kupferschmid AC, et al · · 2024 · cited 13× · PMID 38896810 · DOI 10.1212/wnl.0000000000209506

Verify or expand the search:

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05124392 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 24 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05124392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing